CeMM and Angelini Ventures are joining forces to support CeMM Principal Investigators Laura de Rooij and André Rendeiro in critical lifespan expansion initiatives leveraging a novel academic/entrepreneurial dual-track program. De Rooij and Rendeiro, in collaboration with their teams, will lead an original research program on healthy lifespan expansion. In parallel, they will collaborate on venture creation based on scientific and business insights developed by their work. Venture creation and related business development activities will take place along with scientific research. The expectation is that this double-track initiative will allow for virtuous feedback cycles, propelling innovation through scientific research and bold venture creation goals.
(Vienna, 22 March 2023) Some societal challenges are of such importance to assume the central stage in the public discourse on sustainability and the future of humanity. Such a challenge is aging. Aging is a multidimensional phenomenon, occurring at the individual and population levels of society and on the molecular, cellular, and organ level of the human body. The urgency of dealing with the consequences of aging is illustrated by the fact that in just over ten years from now, more than a third of the population of Italy, one of the world’s most rapidly aging countries, will be over 65 years of age. Expanding the lifespan in which individuals enjoy a healthy status, in which they can be independent and productive, is critical for economic, social, and cultural reasons.
The fundamental mechanisms of aging, at the molecular, cellular, and tissue level, are still unclear and most single theories fail to explain the phenomenon. Scientific leaders are increasingly interested in combining cutting-edge research with immediate value creation and effective societal impact. Laura de Rooij and André Rendeiro will be supported by a network of mentors and experts. At CeMM, the Research Center for Molecular Medicine of the Austrian Academy of Sciences, the team will benefit from access to faculty peers, the center's scientific leadership, a scientific advisory board, and the biotech ventures built in CeMM’s ecosystem of spinoffs. Through Angelini Ventures, the team will be supported to ideate and develop viable start-up companies emerging from their work and have access to an international network of investors, healthcare experts, and industry innovators.
About the Principal Investigators
Laura de Rooij joined CeMM as principal investigator in September 2022. Her lab focuses on deciphering the transcriptomic landscape and role of circulating endothelial cells in health and aging. Laura de Rooij studied Biomedical Sciences at the University of Amsterdam (The Netherlands). She then joined the Stem Cell and Cancer Research Institute at McMaster University in Hamilton (Canada), where she studied the role of RNA binding proteins in leukemic stem cells via an in vivo two-step CRISPR-Cas9-mediated screening approach. For her post-doctoral studies, she returned to Europe to work under the mentorship of Prof. Carmeliet in the lab of Angiogenesis and Vascular Metabolism at VIB-KU Leuven (Belgium). Here she led and contributed to numerous single-cell transcriptome atlases of endothelial cells, generated from a diverse range of tissues, preclinical models, and clinical patient material in health and disease. Her studies have shed new light on the degree of vessel subtype heterogeneity in different tissues, as well as the altered composition and rewired molecular circuitries of endothelial cell subtypes in disease. Moreover, her efforts led to the discovery of previously unknown vascular subtypes and functions, including endothelial cells with a lipid-processing phenotype and potential prognostic relevance in breast cancer, and endothelial cells with a putative pro-fibrotic function in COVID-19. At CeMM, her lab focuses on deciphering the transcriptomic landscape and role of circulating endothelial cells in health and aging.
Read more about Laura de Rooij's research
André Rendeiro is a Principal Investigator at CeMM since June 2022. He leads a group studying how cells interact to generate complex physiology in the human body, and how this changes over the lifespan of individuals and gives rise to disease. To do that, his group develops computational methods for the analysis of spatial data (spatial transcriptomics, highly multiplexed imaging, histopathological images), and its integration with various modalities of molecular, demographic, and clinical data of individuals along their lifespan. Prior to starting his group, André studied in Portugal, Austria, and Norway and earned his PhD in Molecular Medicine at CeMM in Vienna. During his PhD he developed methods for high-throughput cellular profiling and perturbation at single-cell resolution, applying them to leukemia, in the lab of Christoph Bock at CeMM. Between 2020 and 2022 he was a Postdoctoral Associate at the Institute for Precision Medicine and the Institute for Computational Biomedicine at Weill Cornell Medicine in New York. There he developed computational methods for the analysis of highly-multiplexed imaging that incorporate expression, morphology, micro-anatomy, and clinical covariates, in the lab of Olivier Elemento. He led the first tissue-level, single-cell resolution maps of lung pathology during COVID-19, and also contributed to the study of cancer, lung development, and disease, as well as COVID-19 immunology.
Read more about André Rendeiro's research
The CeMM Research Center for Molecular Medicine of the Austrian Academy of Sciences is an international, independent, and interdisciplinary research institution for molecular medicine under the scientific direction of Giulio Superti-Furga. CeMM is oriented toward medical needs and integrates basic research and clinical expertise to develop innovative diagnostic and therapeutic approaches for precision medicine. Research focuses on cancer, inflammation, metabolic and immune disorders, and rare diseases. The Institute's research building is located on the campus of the Medical University and the Vienna General Hospital. www.cemm.at
Angelini Ventures, the venture capital arm of Angelini Industries, is an early-stage investment firm focused on accelerating disruptive innovations and trends in digital health and life sciences. The group will invest €300M across a global portfolio led by investment professionals and advisors in Europe, North America, and Asia. Angelini Ventures has deep domain expertise and leverages a global team, advisors, and strategic partners to help entrepreneurs scale their businesses into transformative category-leading companies. www.angeliniventures.com
Angelini Industries is a multinational industrial group originally founded in Ancona (Italy) in 1919 by Francesco Angelini. Today it is a solid, structured industrial business with around 5,800 employees operating in 21 countries. Angelini Industries operates in the health, industrial technology, and consumer goods businesses. Its investment strategy aimed at growth, constant commitment to research and development, and deep knowledge of markets and business sectors make Angelini Industries an Italian leader in the industries in which it operates. The group is committed to reducing its environmental impact and finding increasingly cutting-edge circular economy solutions. It adopts the most advanced health and safety standards for workers and the most rigorous processes to ensure the highest quality by verifying the entire supply chain: from supplier certification to the control of raw materials, the production process, the finished product, and packaging, to spot checks at the point of sale. For over 100 years, the Angelini family has steered the development of Angelini Industries with an entrepreneurial style typical of Italian family businesses. www.angeliniindustries.com